ABT — Abbott Laboratories

Summary of Abbott Laboratories Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Adjusted Earnings Per Share (EPS): $1.15, consistent with guidance.
• Sales Growth: Increased 3.7% on a comparable basis, with notable contributions from various segments:
  • Diagnostics: 2% growth, with Core Lab Diagnostics up 3% and Cancer Diagnostics up 13%.
  • Nutrition: Slightly ahead of expectations, impacted by lower sales volumes and strategic pricing actions.
  • Established Pharmaceuticals Division (EPD): Grew 9%.
  • Medical Devices: Grew 8.5%, driven by strong performance in cardiovascular devices.
• Gross Margin: Adjusted gross margin at 56.3%.
• Foreign Exchange Impact: Favorable 4% on sales year-over-year.

2. Strategic Updates and Business Highlights

• Acquisition of Exact Sciences: Completed on March 23, 2026, expected to add approximately $3 billion in sales for 2026 and strengthen Abbott's position in cancer diagnostics.
• Pipeline Achievements: Successful launches and approvals in medical devices, including new PFA catheters and ongoing clinical trials for innovative products.
• Focus on Growth Areas: Emphasis on accelerating growth in Core Lab Diagnostics and Nutrition, with new product launches expected to drive improvement.

3. Forward Guidance and Outlook

• Full-Year Sales Growth Outlook: Adjusted to 6.5% to 7.5%, incorporating Exact Sciences into the comparable basis.
• Adjusted EPS Guidance: Revised to a midpoint of $5.48, reflecting dilution from the Exact Sciences acquisition.
• Second Quarter EPS Forecast: Expected to be between $1.25 and $1.31.
• Growth Acceleration: Management remains confident in achieving an acceleration in growth in the second half of the year, driven by strategic initiatives and market recovery.

4. Bad News, Challenges, or Points of Concern

• Weaker Respiratory Season: Impacted sales in the Rapid and Molecular Diagnostics segment, which saw a 10% decline.
• Nutrition Business Challenges: Transitioning back to growth after strategic pricing actions; early signs of recovery noted, but still in progress.
• Competitive Pressures: Increased competition in the Structural Heart and Electrophysiology markets, necessitating improved execution.
• Market Conditions: Ongoing uncertainties related to macroeconomic factors, including potential impacts from geopolitical events, although no immediate effects on costs were observed.

5. Notable Q&A Insights

• Guidance Philosophy: Management emphasized transparency in guidance, incorporating Exact Sciences into historical performance for clearer visibility.
• Continuous Glucose Monitoring (CGM) Market: Acknowledged current challenges but expressed optimism about future growth driven by new product launches and reimbursement changes.
• Exact Sciences Integration: Management is optimistic about sustaining growth in Cologuard and expanding into international markets, with a focus on comprehensive cancer diagnostics.
• Core Lab Business Recovery: Positive trends noted in U.S. and international markets, with expectations for mid-single-digit growth in Core Lab Diagnostics for the full year.

Overall, Abbott Laboratories reported solid financial results in Q1 2026, with strategic initiatives aimed at driving future growth, despite facing challenges in certain segments and external market pressures.